The top 10 biopharma stock gainers and losers for the week.

BioWorld tracked a total of 295 phase I, II and III clinical news items in January, a rise of 39% compared with the number recorded during the pre-pandemic month of January 2020.

Biopharmaceutical companies developing cancer therapies had a productive year with about 38% of the record 53 new medicines approved by the FDA targeting oncology indications. This was one of the contributing factors for the 21% growth in the valuation of the price weighted BioWorld Cancer index in 2020.

A quick look back at top stories.

Following a $59.7 billion record-breaking year, med-tech financings in 2021 have already raised 56% more than the amount recorded during the pre-pandemic early weeks of 2020.